title: Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
abstract: Pre-clinical HIV-1 vaccine protocols, using multiple vaccine modalities and a potent adjuvant were assessed for vaccine efficacy in an experimental HIV-1 challenge model. C57Bl/6 mice were immunized with DNA plasmids encoding HIV-1 gp140, Gag and Tat alone or in combination with the corresponding recombinant proteins formulated in the adjuvant MF59. HIV-1 DNA alone or a DNA prime protein boost schedule resulted in complete protection against challenge with HIV-1/MuLV-infected murine cells. Although HIV-1 protein immunization in combination with MF59 resulted in partial protection, the DNA priming seemed to be crucial for obtaining full protection against the challenge. It is likely that the partial protection seen after immunization with protein alone is, to a certain extent, due to effects of the adjuvant since some animals that received the adjuvant MF59 alone were protected from the challenge. For the most part, antigen-specific cell-mediated immune responses as detected in the spleen (in contrast to responses detected in peripheral blood) of immunized animals appeared to be associated with protection in this study.
authors: Swedish Institute for Infectious Disease Control, Stockholm, Sweden. andreas.brave@smi.ki.se
authors: Andreas
authors: A
authors: Bråve
authors: Jorma
authors: J
authors: Hinkula
authors: Aurelio
authors: A
authors: Cafaro
authors: Lars E
authors: LE
authors: Eriksson
authors: Indresh K
authors: IK
authors: Srivastava
authors: Mauro
authors: M
authors: Magnani
authors: Barbara
authors: B
authors: Ensoli
authors: Susan W
authors: SW
authors: Barnett
authors: Britta
authors: B
authors: Wahren
authors: Erik
authors: E
authors: Rollman
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D000276:Adjuvants, Immunologic; D000818:Animals; D004195:Disease Models, Animal; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology*; D015696:Gene Products, tat / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000472:pathogenicity*; D006801:Humans; D007114:Immunization; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D009052:Leukemia Virus, Murine; D051379:Mice; D008810:Mice, Inbred C57BL / Q000235:genetics; D008822:Mice, Transgenic; D011136:Polysorbates; D013185:Squalene; D013601:T-Lymphocytes / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015683:Gene Products, gag; D015696:Gene Products, tat; D015483:HIV Antibodies; D007074:Immunoglobulin G; C089950:MF59 oil emulsion; D011136:Polysorbates; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1; D013185:Squalene